

# Nitazoxanide

Catalog No: tcsc2164



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

55981-09-4

**Formula:**

$C_{12}H_9N_3O_5S$

**Pathway:**

Autophagy;Anti-infection

**Target:**

Autophagy;Influenza Virus

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

NTZ;NSC 697855

**Observed Molecular Weight:**

307.28


## Product Description

Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC<sub>50</sub> for canine influenza virus ranges from 0.17 to 0.21  $\mu$ M).

Target: Others

Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. In vitro studies demonstrated much broader activity. Dr. Rossignol co-founded Romark Laboratories, with the goal of bringing nitazoxanide to market as an anti-parasitic drug. Initial studies in the USA were conducted in collaboration with Unimed Pharmaceuticals, Inc. (Marietta, GA) and focused on development of the drug for treatment of cryptosporidiosis in AIDS.

The anti-protozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme dependent electron transfer reaction which is essential to anaerobic energy metabolism. It has also been shown to have activity against influenza A virus in vitro. The mechanism appears to be by selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to endoglycosidase H digestion. This impairs hemagglutinin intracellular trafficking and insertion of the protein into the host plasma membrane.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!